Ferozsons Laboratories Valuation

Is FEROZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FEROZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FEROZ (PKR346.7) is trading above our estimate of fair value (PKR14.79)

Significantly Below Fair Value: FEROZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FEROZ?

Key metric: As FEROZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for FEROZ. This is calculated by dividing FEROZ's market cap by their current earnings.
What is FEROZ's PE Ratio?
PE Ratio	23.5x
Earnings	PK₨640.44m
Market Cap	PK₨15.07b

FEROZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	8.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does FEROZ's PE Ratio compare to its peers?

The above table shows the PE ratio for FEROZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.3x
CPHL Citi Pharma	10.9x	n/a	PK₨10.3b
HPL Hoechst Pakistan	15.5x	n/a	PK₨25.1b
HINOON Highnoon Laboratories	15.7x	n/a	PK₨47.4b
BFBIO BF Biosciences	31x	n/a	PK₨12.4b
FEROZ Ferozsons Laboratories	23.5x	n/a	PK₨15.1b

Price-To-Earnings vs Peers: FEROZ is expensive based on its Price-To-Earnings Ratio (23.5x) compared to the peer average (18.3x).

Price to Earnings Ratio vs Industry

How does FEROZ's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: FEROZ is good value based on its Price-To-Earnings Ratio (23.5x) compared to the Asian Pharmaceuticals industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is FEROZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FEROZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate FEROZ's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.